SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

2024.01.14
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.
Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

2024.01.14
The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.

Unresolved Issues in Pediatric Hepatitis B Treatment Guidelines

2024.01.12
China is a high-incidence country for hepatitis B virus (HBV), with mother-to-child transmission being a significant route of HBV infection in children. If infected with HBV, 15% to 25% of children may develop into chronic carriers, posing risks of liver cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of the disease and taking timely and effective treatment measures are of great practical significance. From November 17-19, 2023, the "15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference" was grandly held in Chongqing. It was hosted by the Chinese Medical Journal Company Ltd., organized by the Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis. At the conference, Dr. Junliang Fu of the Fifth Medical Center of the Chinese People's Liberation Army General Hospital sparked intense interest with his thematic discussion on hot issues in pediatric HBV clinical treatment. We are honored to have Dr. Junliang Fu for an in-depth interview, the contents of which are compiled here for our readers.

The Treatment and Clinical Cure of Childhood Hepatitis B

2024.01.10
China is a country with a high incidence of hepatitis B, and mother-to-child transmission is an important route for children in China to contract the hepatitis B virus (HBV). Although chronic HBV infection in childhood rarely progresses to active hepatitis, there is still a risk of developing cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of childhood hepatitis B and taking effective prevention and control measures are particularly important to reduce the incidence of childhood hepatitis B in China and promote healthy growth. In recent years, as the goal of clinical cure for hepatitis B has gradually gained more attention, the issue of clinical cure for childhood hepatitis B has also received increasing focus. At the recently concluded "15th Academic Conference on Antiviral Therapy Difficulties and Hotspots in Chronic Viral Hepatitis," Dr. Fusheng Wang from the Fifth Medical Center of the PLA General Hospital presented a special report on "Treatment and Clinical Cure of Childhood Hepatitis B," offering an in-depth analysis of these issues.
From “Clinical Cure” to “Disease Cure” – The Long-term Treatment of Chronic Hepatitis B

From “Clinical Cure” to “Disease Cure” – The Long-term Treatment of Chronic Hepatitis B

2024.01.09
From November 17-19, 2023, the "15th Chronic Viral Hepatitis Antiviral Treatment Difficulties and Hotspots Academic Conference" was grandly held in Chongqing. Sponsored by the Chinese Medical Journal Co., Ltd., organized by the Editorial Department of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology of the Chinese Medical Association (CMA), the Second Affiliated Hospital of Chongqing Medical University, and the Viral Hepatitis Research Institute of Chongqing Medical University, the conference focused on chronic viral hepatitis treatment and high-quality development of the discipline, providing a platform for information exchange and interaction among frontline clinicians and clinical researchers. Dr. Xiaoguang Dou from Shengjing Hospital of China Medical University, the chairman of the conference, shared the highlights and engaged in an in-depth interview on the hot topic of chronic hepatitis B clinical treatment. The content is organized for the readers' benefit.
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

2024.01.03
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress Dr. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve antiviral treatment of hepatitis B and C. Dr. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection. In addition, Dr Wei is involved in Kidney Disease Improving Global Outcome to develop a Guideline for HCV Infection, Diagnosis, Prevention and Management in Kidney Disease and contributes to APASL for hepatitis C guideline.
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies

Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies

2024.01.02
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies Tarik Asselah is a Full Professor of Medicine and Hepatology at Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, France. Tarik Asselah is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation). He is MD and also holds a PhD in virology. His fields of research include chronic liver diseases, translational medicine and treatment of HBV, HCV and HDV infections with new direct-acting antivirals, for which he has been involved as a coordinator/principal investigator in several clinical trials. He coordinated major international clinical trials on HCV, HBV and HDV infections. He has published more than 250 articles in the field of chronic liver diseases in major journals (NEJM, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…). (H-index = 60). He has been selected as a rising star in Gastroenteology in 2009 by the United European Gastroenterology (UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for the Liver Disease (AFEF), and for his leadership in Hepatology in 2019 from the Czech Hepatology Society.
Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress

Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress

2024.01.02
Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress Tom Hemming Karlsen (MD, PhD) is a clinical specialist in internal medicine and gastroenterology working in Oslo, Norway. Dr. Karlsen graduated from medical school at the University of Bergen in 1997. In 2012 he was appointed professor of gastroenterology at the University of Bergen and in 2014 he was appointed full professor of internal medicine at the University of Oslo. Within the Oslo University Hospital he is Research Head of the Division of Surgery, Inflammatory medicine and Transplantation, and is also leader of the Norwegian PSC research center at the Department of Transplantation Medicine and Research Institute of Internal Medicine. Clinically, he works as a senior consultant within transplant hepatology at the Section of Gastroenterology at the Department of Transplantation Medicine
Treatment Options for Early Liver Cancer, Strategies for Preventing Recurrence, and the Application of New Molecular Technologies in Tumour

Treatment Options for Early Liver Cancer, Strategies for Preventing Recurrence, and the Application of New Molecular Technologies in Tumour

2024.01.02
Early treatment is the key to improving the survival rate of liver cancer patients. At the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Fabio Piscaglia from the University of Bologna, Italy, presented the latest developments in the treatment of early-stage hepatocellular carcinoma (HCC) in a special session titled "Treatment of early stage HCC in 2023." Hepatology Digest had the privilege of inviting Professor Fabio Piscaglia to share insights into HCC treatment strategies, strategies for preventing HCC recurrence, and the current status and prospects of emerging technologies for tumour molecular characterization.
Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

2023.12.22
From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was held in Boston, USA. Professor Jing Zhang and her team from Beijing Youan Hospital, Capital Medical University, have long focused on scientific research in chronic liver diseases. Seven research findings from the team were included in the conference and presented in poster form, covering non-alcoholic fatty liver disease (NAFLD) [1-3], cirrhosis [4-5], and hepatitis C [6-7]. "Hepatology Digest" had the privilege of inviting Professor Jing Zhang for an interview at the conference to introduce the research findings, share insights into clinical research, and discuss topics of interest and future research directions. The interview video and some research content are shared below.